Streetbeat News

Price Targets

PBA

RBC Capital analyst Maurice Choy has reiterated an Outperform rating on Pembina Pipeline (TSX:PPL) and maintained a C$58 price target.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 2:41 pm

FSV

RBC Capital analyst Tom Callaghan has maintained an Outperform rating on FirstService (NASDAQ:FSV) and increased the price target from $178 to $187.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 2:23 pm

ENB

RBC Capital analyst Maurice Choy has reiterated an Outperform rating on Enbridge (TSX:ENB) and maintained a price target of C$55.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 2:21 pm

DPM

RBC Capital analyst Wayne Lam has maintained an Outperform rating on Dundee Precious Metals but has reduced the price target from C$15 to C$14.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 2:19 pm

CCJ

RBC Capital analyst Andrew Wong has reiterated an Outperform rating on Cameco (TSX:CCO) and maintained a price target of C$70. No additional details or analysis were provided in the article.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 2:18 pm

FDX

Stephens & Co. analyst Jack Atkins has maintained an Overweight rating on FedEx (NYSE:FDX) but has reduced the price target from $330 to $320.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 2:09 pm

AAPL

Wedbush analyst Daniel Ives has reiterated an Outperform rating on Apple Inc. (NASDAQ:AAPL) and maintained a price target of $250.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 2:02 pm

GMED

Five financial analysts have provided diverse ratings for Globus Medical (NYSE:GMED) over the last three months, with recent updates showing a mix of bullish and indifferent stances. The average 12-month price target for GMED has increased to $67.6, with a high estimate of $86.00 and a low of $53.00. Analysts from Canaccord Genuity, Morgan Stanley, Truist Securities, Roth MKM, and Barclays have adjusted their ratings and price targets, reflecting their latest views on the company's performance and market conditions. Globus Medical, a medical device company, has seen significant revenue growth but faces challenges with net margin, ROE, and ROA below industry standards, despite a conservative debt management approach.

Portfolio Pulse from Benzinga Insights

December 20, 2023 | 2:00 pm

UAL

United Airlines Holdings (NASDAQ:UAL) has been the subject of diverse analyst ratings over the past three months, with 10 analysts offering ratings ranging from bullish to indifferent. The average 12-month price target is $64.7, with a high of $98.00 and a low of $40.00, reflecting a 7.57% decrease in the average target. Analysts from firms like Raymond James, JP Morgan, Susquehanna, Citigroup, Morgan Stanley, Jefferies, and Bernstein have adjusted their ratings and price targets, mostly lowering them. United Airlines has shown strong financial performance with a revenue growth rate of 12.48%, a net margin of 7.86%, an ROE of 13.75%, and an ROA of 1.55%, along with a debt-to-equity ratio of 3.96.

Portfolio Pulse from Benzinga Insights

December 20, 2023 | 2:00 pm